GSK2838232HIV-1 maturation inhibitor CAS# 1443461-21-9 |
- PF-04691502
Catalog No.:BCC3837
CAS No.:1013101-36-4
- NVP-BGT226
Catalog No.:BCC3827
CAS No.:1245537-68-1
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- CUDC-907
Catalog No.:BCC2154
CAS No.:1339928-25-4
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- XL147
Catalog No.:BCC2487
CAS No.:956958-53-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1443461-21-9 | SDF | Download SDF |
PubChem ID | 89634981 | Appearance | Powder |
Formula | C48H73ClN2O6 | M.Wt | 809.56 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | 4-[[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(3-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid | ||
SMILES | CC(C)C1=C2C3CCC4C5(CCC(C(C5CCC4(C3(CCC2(CC1=O)C(CN(CCN(C)C)CC6=CC(=CC=C6)Cl)O)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C | ||
Standard InChIKey | DSNMRZSQABDJDK-PZFKGGKESA-N | ||
Standard InChI | InChI=1S/C48H73ClN2O6/c1-30(2)40-34(52)26-48(37(53)29-51(24-23-50(10)11)28-31-13-12-14-32(49)25-31)22-21-46(8)33(41(40)48)15-16-36-45(7)19-18-38(57-39(54)27-43(3,4)42(55)56)44(5,6)35(45)17-20-47(36,46)9/h12-14,25,30,33,35-38,53H,15-24,26-29H2,1-11H3,(H,55,56)/t33-,35+,36-,37+,38+,45+,46-,47-,48+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
GSK2838232 Dilution Calculator
GSK2838232 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.2352 mL | 6.1762 mL | 12.3524 mL | 24.7048 mL | 30.881 mL |
5 mM | 0.247 mL | 1.2352 mL | 2.4705 mL | 4.941 mL | 6.1762 mL |
10 mM | 0.1235 mL | 0.6176 mL | 1.2352 mL | 2.4705 mL | 3.0881 mL |
50 mM | 0.0247 mL | 0.1235 mL | 0.247 mL | 0.4941 mL | 0.6176 mL |
100 mM | 0.0124 mL | 0.0618 mL | 0.1235 mL | 0.247 mL | 0.3088 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK2838232 is an HIV-1 maturation inhibitor [1] [2].
HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. Maturation inhibitors bind the gag protein, which leads to the formation of immature, noninfectious virus particles incapable of infecting other cells. Also, maturation inhibitors inhibit HIV infections with resistance.
GSK2838232 is a HIV-1 maturation inhibitor and is active against a broad range of isolates, including those resistant to bevirimat [1]. GSK2838232 was developed for the treatment of chronic HIV infection. A phase I study in HIV-negative individuals had been completed. Single doses of 5, 10 or 20 mg GSK2838232 were used to evaluate the initial safety, tolerability, pharmacokinetics profile, and the effects of food and ritonavir on GSK2838232’s bioavailability and pharmacokinetics [2].
References:
[1]. Olender SA, Taylor BS, Wong M, et al. CROI 2015: Advances in Antiretroviral Therapy. CROI 2015 Highlights: Antiretroviral Therapy Volume 23 Issue 1 March/April 2015.
[2]. Horn T, Collins S. The Antiretroviral Pipeline. Antiretrovirals, 2014 PIPELINE REPORT.
- CCG 203971
Catalog No.:BCC5601
CAS No.:1443437-74-8
- Nemoralisin C
Catalog No.:BCN7680
CAS No.:1443421-84-8
- YM 26734
Catalog No.:BCC7396
CAS No.:144337-18-8
- Trilepisflavan
Catalog No.:BCN6786
CAS No.:1443218-16-3
- 1-Deazaadenosine
Catalog No.:BCC6204
CAS No.:14432-09-8
- ML 337
Catalog No.:BCC6345
CAS No.:1443118-44-2
- Dehydroadynerigenin glucosyldigitaloside
Catalog No.:BCN1568
CAS No.:144223-70-1
- YYA-021
Catalog No.:BCC5346
CAS No.:144217-65-2
- 1-Acetyl-4-methylpiperazine hydrochloride
Catalog No.:BCC6615
CAS No.:144205-68-5
- Indoxacarb
Catalog No.:BCN2263
CAS No.:144171-61-9
- Ledipasvir acetone
Catalog No.:BCC4046
CAS No.:1441674-54-9
- Eprosartan Mesylate
Catalog No.:BCC4658
CAS No.:144143-96-4
- 8-(7-Hydroxy-3,7-dimethyl-2,5-octadienyloxy)psoralen
Catalog No.:BCN1567
CAS No.:144398-34-5
- 3-Oxopomolic acid methyl ester
Catalog No.:BCN3723
CAS No.:14440-23-4
- Canophyllal
Catalog No.:BCN7441
CAS No.:14440-40-5
- 3-O-(E)-p-Coumaroylbetulin
Catalog No.:BCN6247
CAS No.:144424-80-6
- Aflavarin
Catalog No.:BCN7410
CAS No.:144429-67-4
- Goniodiol 8-acetate
Catalog No.:BCN4787
CAS No.:144429-71-0
- Beta-Aflatrem
Catalog No.:BCN6699
CAS No.:144446-23-1
- Clopidogrel Related Compound A
Catalog No.:BCN2687
CAS No.:144457-28-3
- Tirofiban
Catalog No.:BCC4868
CAS No.:144494-65-5
- Licochalcone C
Catalog No.:BCN6334
CAS No.:144506-14-9
- Rotundatin
Catalog No.:BCN7856
CAS No.:144506-16-1
- Cannabisin D
Catalog No.:BCN2547
CAS No.:144506-19-4
The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.[Pubmed:29930812]
Pharmacol Res Perspect. 2018 Jun 5;6(4):e00408.
This work aimed to assess the safety, tolerability, pharmacokinetics (PK), and relative bioavailability of GSK2838232, an investigational HIV maturation inhibitor. GSK2838232 was administered over four dose-escalation studies in healthy subjects which assessed single oral doses (5-250 mg) and repeat doses (up to 200 mg once or twice daily) +/-100 mg ritonavir (RTV) once daily. GSK2838232 administration (up to 250 mg) to 124 subjects across four studies resulted in few mild adverse events (AEs) with similar frequencies to placebo. There were no clearly identified drug-related AEs. GSK2838232 tested fasted was quickly absorbed with a tmax of 2-3 hours. With food, the absorption was delayed and more variable, with ~60% increase in AUC and Cmax. Overall, following single doses GSK2838232 AUC and Cmax generally exhibited proportional PK from 50 to 100 mg dose without RTV and from 50 to 250 mg with RTV and following repeated doses of 20-200 mg with RTV. In relative bioavailability studies, a micronized formulation was found to be suitable for development. At steady state, RTV increased GSK2838232 AUC and Cmax by 10- and 3-fold, respectively. Half-life was prolonged from ~17 hours nonboosted to ~34 hours with RTV. This boosting effect was also seen in repeat-dose GSK2838232 studies, which achieved the targeted plasma exposure with GSK2838232 as a once-daily regimen of up to 200 mg with RTV. The results of these studies demonstrated a favorable safety and PK profile for GSK2838232 and support its investigation for the treatment of HIV infection.